Cerevel Therapeutics

AbbVie's Parkinson's prospect improves motor function in ph. 3

AbbVie has completed a hat trick of phase 3 wins for its Parkinson’s disease prospect tavapadon, teeing the drugmaker up to file for approval in 2025.

Nick Paul Taylor Dec 9, 2024 9:34am

failure crash no fail rocket cancelled end

AbbVie's $9B schizophrenia prospect flunks phase 2 trials

Nov 11, 2024 10:06am

Soccer ball flying into a net scoring a goal

AbbVie Parkinson's drug from $8.7B Cerevel buyout scores

Sep 26, 2024 10:45am

Bain unveils $3B fund for life science companies

Sep 10, 2024 11:20am

alzheimers brain neurodegenerative memory head

AbbVie axes Alzheimer's program amid 'evolving landscape'

Jul 25, 2024 10:49am

microphone pass stage spotlight sing music perform pass the mic

AbbVie-bound Cerevel reports phase 3 Parkinson's victory

Apr 18, 2024 8:34am